* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Medpace Holdings's PEG Ratio or its related term are showing as below:
MEDP'
s PEG Ratio Range Over the Past 10 Years
Min: 0.82 Med: 1.41 Max: 2.51
Current: 1.17
During the past 11 years, Medpace Holdings's highest PEG Ratio was 2.51. The lowest was 0.82. And the median was 1.41.
MEDP's PEG Ratio is ranked better than 66.67% of 51
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.09
vs MEDP: 1.17
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Medpace Holdings PEG Ratio Historical Data
The historical data trend for Medpace Holdings's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medpace Holdings's PEG Ratio
For the Diagnostics & Research subindustry, Medpace Holdings's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings's PEG Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's PEG Ratio falls into.
Medpace Holdings PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Medpace Holdings (NAS:MEDP) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Medpace Holdings PEG Ratio Related Terms
Thank you for viewing the detailed overview of Medpace Holdings's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEDP has been successfully added to your 